Recombinant Human Interleukin-12 receptor subunit beta-1 (IL12RB1)

What is IL12RB1 and what are its primary functions in immune signaling?

IL12RB1, also known as CD212 antigen, is a type I transmembrane protein belonging to the hemopoietin receptor superfamily. It functions as an interleukin receptor that binds interleukin-12 with low affinity and is integral to IL-12 signal transduction . The protein contains 5 fibronectin domains in the extracellular domain (ECD), a single transmembrane domain, and a box 1 motif in the cytoplasmic region .

IL12RB1 serves dual critical functions in cytokine signaling:

• When associated with IL12RB2, it forms a functional high-affinity receptor complex for IL-12, which is essential for IL-12 signal transduction .

• It associates with IL23R to form the interleukin-23 receptor complex, functioning in IL-23 signal transduction through activation of the Jak-Stat signaling cascade .

The mature extracellular domain of human IL12RB1 shares 51% amino acid identity with mouse and rat IL12RB1, an important consideration for cross-species research applications .

What experimental systems are most appropriate for studying recombinant IL12RB1 function?

For studying recombinant IL12RB1 function, researchers should consider several experimental systems:

• Binding Assays: Functional ELISA is an effective method to measure the binding ability of recombinant IL12RB1. For example, recombinant human IL-12 R beta 1 His-tag binds to recombinant human IL-12 with an ED50 of 3.00-30.0 ng/mL .

• Expression Systems: Both mammalian expression systems (such as NS0 cells) and bacterial expression systems can be used to produce recombinant IL12RB1, though mammalian systems may provide better post-translational modifications .

• Protein Analysis: SDS-PAGE under reducing and non-reducing conditions is recommended for validating protein integrity, with recombinant human IL-12 R beta 1 His-tag protein showing bands at 62-79 kDa .

• Cell Culture Models: Activated T cells, NK cells, and B cells naturally express IL12RB1 and are suitable for functional studies .

• Reconstitution Protocols: For optimal activity, reconstitute lyophilized recombinant IL12RB1 at approximately 200 μg/mL in sterile PBS and avoid repeated freeze-thaw cycles .

How does the structure of recombinant IL12RB1 influence its experimental applications?

The structure of recombinant IL12RB1 significantly impacts its experimental applications in several ways:

• Extracellular Domain Focus: Most commercially available recombinant IL12RB1 proteins consist of the extracellular domain (typically Cys24-Glu540) with various tags (His-tag or Fc chimera) . This is because the extracellular portion contains the cytokine-binding region essential for physical association with IL-12/IL-23 .

• Tag Selection: The choice of tag affects experimental utility:

  • His-tagged versions (showing bands at 62-79 kDa) are useful for purification and detection

  • Fc chimera versions (typically around 110 kDa) can enhance stability and provide alternative detection methods

• Glycosylation Patterns: Since IL12RB1 is a glycoprotein, expression systems that maintain proper glycosylation (such as NS0 cells) may be critical for studies requiring physiologically relevant protein conformation .

• Functional Domains: The protein contains 5 fibronectin domains in the extracellular region that are critical for interactions with IL-12 and IL-23 . Research examining specific domain functions should consider using domain-specific constructs.

• Protein Stability: The cytoplasmic portion that acts in concert with IL-12Rβ2/IL-23R to transmit intracellular signals via TYK2 and JAK2 is not typically included in recombinant proteins but must be considered when designing cell-based signaling studies .

What are the methodological approaches for investigating IL12RB1 isoforms and their differential functions?

Recent research has revealed that human leukocytes express multiple isoforms from the IL12RB1 gene, similar to observations in mice . To investigate these isoforms and their differential functions, researchers should consider these methodological approaches:

• Isoform Identification:

  • RT-PCR with isoform-specific primers spanning different exon junctions

  • RNA-Seq analysis with specialized splice-junction detection algorithms

  • Western blotting with antibodies recognizing different domains to detect size variants

• Expression Profiling:

  • qPCR assays to quantify relative abundance of different isoforms across cell types

  • Single-cell RNA-Seq to determine cell-specific isoform expression patterns

  • Stimulation experiments with inflammatory mediators to assess dynamic regulation of isoform expression

• Functional Characterization:

  • Generation of isoform-specific expression constructs

  • CRISPR-based isoform-specific knockout models

  • Co-immunoprecipitation studies to determine isoform-specific interaction partners

• Signaling Analysis:

  • Phospho-flow cytometry to measure activation of downstream signaling molecules (JAK-STAT pathway)

  • Reporter assays with isoform-specific expression to measure differential activation of signaling pathways

  • Proximity ligation assays to visualize interactions between isoforms and signaling molecules

Research indicates that inflammatory signals direct the expression of specific isoforms, suggesting functional specialization . Methodologically sound investigations should include appropriate stimulation conditions (e.g., mycobacterial antigens, IL-12, IL-23) and time-course analyses to capture dynamic regulation.

How can researchers address the dual role of IL12RB1 in pathogen resistance and autoimmunity within experimental design?

IL12RB1 presents a fascinating research challenge as it promotes both protective immunity against intracellular pathogens and pathological autoimmunity . To address this dual role experimentally:

• Model Selection:

  • Use paired infection and autoimmunity models (e.g., M. tuberculosis infection versus experimental autoimmune encephalomyelitis)

  • Consider humanized mouse models expressing human IL12RB1 variants to better translate findings

  • Develop organoid systems incorporating immune cells to model tissue-specific responses

• Genetic Approaches:

  • Utilize inducible or conditional IL12RB1 knockout systems to temporally control expression

  • Generate knock-in models with specific polymorphisms associated with either increased infection susceptibility or autoimmunity risk

  • Employ CRISPR-based epigenetic modifiers to alter IL12RB1 expression without changing genetic sequence

• Signaling Dissection:

  • Use pathway-specific inhibitors to block IL-12 versus IL-23 signaling downstream of IL12RB1

  • Develop biased ligands that preferentially activate protective versus pathological signaling pathways

  • Perform phosphoproteomic analysis to identify differential signaling nodes

• Translational Approaches:

  • Analyze patient samples with IL12RB1 deficiencies for biomarkers of differential immune activation

  • Develop ex vivo assays using patient-derived cells to test targeted interventions

  • Design domain-specific blocking antibodies that selectively inhibit IL12RB1 interactions

The experimental design should account for contextual factors that may shift IL12RB1 function toward protection or pathology, including:

• Tissue microenvironment

• Concurrent cytokine milieu

• Epigenetic regulation

• Presence of specific microbial signals or damage-associated molecular patterns

What methodological considerations are important when studying the epigenetic regulation of IL12RB1?

Recent data demonstrate that individual variability in IL12RB1 function is introduced at the epigenetic level, among others . When investigating epigenetic regulation of IL12RB1, researchers should consider:

• Chromatin Analysis:

  • Perform chromatin immunoprecipitation sequencing (ChIP-seq) for histone modifications (H3K4me3, H3K27ac, H3K27me3) at the IL12RB1 locus

  • Use ATAC-seq to assess chromatin accessibility at promoter and enhancer regions

  • Apply CUT&RUN or CUT&Tag for higher resolution mapping of transcription factor binding sites

• DNA Methylation Assessment:

  • Utilize bisulfite sequencing to map CpG methylation patterns in the IL12RB1 promoter region

  • Perform methylation-specific PCR for targeted analysis of key regulatory regions

  • Consider single-cell methylation analysis to capture cellular heterogeneity

• Enhancer Mapping:

  • Employ chromosome conformation capture techniques (4C, Hi-C) to identify long-range interactions

  • Use enhancer reporter assays to validate functional enhancer elements

  • Perform CRISPR-based epigenome editing to test the functional significance of specific regulatory elements

• Experimental Variables to Control:

  • Cell activation state (as IL12RB1 expression is activation-dependent)

  • Cell culture conditions that might affect epigenetic marks

  • Donor genetic background when using primary human cells

  • Previous exposure to inflammatory stimuli that might establish epigenetic memory

• Data Integration:

  • Correlate epigenetic patterns with mRNA expression levels and isoform usage

  • Integrate genetic polymorphism data with epigenetic profiles

  • Analyze conservation of regulatory elements across species

This multilayered approach can help elucidate how epigenetic mechanisms contribute to the variable function of IL12RB1 in different immunological contexts and disease states.

What experimental approaches should be considered when studying IL12RB1-dependent signaling in the context of mycobacterial infection?

Given the critical role of IL12RB1 in resistance to mycobacterial infections , researchers should consider these experimental approaches:

• Infection Models:

  • In vitro: Primary human macrophages or dendritic cells infected with mycobacterial strains

  • Ex vivo: Precision-cut lung slices from IL12RB1-sufficient or deficient models

  • In vivo: Humanized mouse models expressing wild-type or variant IL12RB1

• Signaling Analysis:

  • Temporal profiling of JAK-STAT pathway activation following infection

  • Comparison of IL-12 versus IL-23 signaling components

  • Analysis of cross-talk with other pathways (e.g., TLR, NOD)

• Cellular Readouts:

  • Intracellular bacterial burden quantification

  • T-cell polarization assays (Th1/Th17 balance)

  • Inflammasome activation and IL-1β/IL-18 production

• Genetic Manipulation Approaches:

  • CRISPR-mediated knockout of IL12RB1 in primary cells

  • Reconstitution with wild-type versus mutant IL12RB1

  • Isoform-specific expression systems

• Translational Considerations:

  • Analysis of samples from patients with IL12RB1 deficiency

  • Correlation with clinical outcomes in tuberculosis cohorts

  • Development of ex vivo diagnostic assays

When designing these experiments, researchers should consider that IL12RB1 deficiency impacts both IL-12 and IL-23 signaling, necessitating careful dissection of which pathway is primarily responsible for observed phenotypes in mycobacterial infection contexts.

How can researchers effectively compare the functional differences between recombinant IL12RB1 produced in different expression systems?

Different expression systems can yield recombinant IL12RB1 with varying functionality. To effectively compare these differences:

• Systematic Characterization Protocol:

  • Perform side-by-side binding assays (surface plasmon resonance or ELISA) with IL-12 and IL-23

  • Analyze glycosylation patterns using lectin blots or mass spectrometry

  • Assess protein stability under various storage conditions and thermal stress

  • Compare signaling potency in reporter cell lines

• Quality Control Metrics:

  • Purity assessment by silver-stained SDS-PAGE (should be >95%)

  • Endotoxin testing (<0.10 EU per 1 μg of protein by LAL method)

  • Secondary structure analysis by circular dichroism spectroscopy

  • Aggregation assessment by dynamic light scattering

• Functional Comparisons:

  • Receptor complex formation efficiency with IL12RB2 or IL23R

  • Downstream signaling activation (STAT4 phosphorylation for IL-12; STAT3 for IL-23)

  • Biological activity in relevant cell types (T cells, NK cells)

• Expression System Considerations:

  • Mammalian systems (NS0, CHO, HEK293) provide proper glycosylation but at higher cost

  • Bacterial systems offer higher yield but lack post-translational modifications

  • Insect cell systems represent a middle ground for certain applications

• Application-Specific Testing:

  • For structural studies: protein homogeneity and crystallizability

  • For binding studies: consistent affinity measurements

  • For cellular assays: endotoxin levels and bioactivity

When reporting results, researchers should clearly document the expression system used, purification methods, and quality control data to facilitate reproducibility and appropriate interpretation of findings.

What are the methodological approaches for studying IL12RB1 interaction with novel IL12p40-heterodimers beyond IL-12 and IL-23?

Recent discoveries of multiple novel IL12p40-heterodimers suggest IL12RB1 may be involved in additional signaling pathways yet to be discovered . To investigate these novel interactions:

This systematic approach can help identify and characterize novel IL12p40-containing cytokines that signal through IL12RB1, potentially revealing new therapeutic targets for immune-mediated diseases.

How do different recombinant tags affect the structural integrity and functional properties of IL12RB1 in experimental settings?

The choice of recombinant tag can significantly impact IL12RB1 structure and function:

• Structural Impacts:

  • His-tags (typically 6× histidine) add minimal size but may affect protein folding near the tagged terminus

  • Fc fusion proteins (human IgG1 Pro100-Lys330) substantially increase molecular weight (110 kDa vs. 62-79 kDa for His-tagged)

  • Tag position (N- versus C-terminal) may differentially affect binding domain accessibility

• Functional Comparison:

  • Binding affinity measurements using surface plasmon resonance or ELISA

  • Receptor complex formation efficiency with IL12RB2 or IL23R

  • Downstream signaling activation in reporter cell systems

• Methodological Considerations:

  • For crystallization: smaller tags (His) generally preferred

  • For in vivo studies: Fc fusion may extend half-life but introduce potential Fc receptor interactions

  • For binding studies: compare multiple tag configurations to identify potential interference

• Tag Removal Options:

  • Incorporation of protease cleavage sites (TEV, thrombin, etc.)

  • On-column cleavage protocols

  • Assessment of functional differences pre- and post-cleavage

• Application-Specific Selection:

  • For detection: fluorescent protein fusions or epitope tags

  • For purification: affinity tags (His, GST, MBP)

  • For stabilization: Fc fusions or larger solubility enhancers

Researchers should systematically compare multiple tagged versions when establishing new experimental systems to identify the optimal configuration for their specific application.

What methodological approaches are most effective for studying IL12RB1 polymorphisms associated with disease susceptibility?

IL12RB1 polymorphisms have been associated with susceptibility to numerous diseases, including atopic dermatitis, Crohn's disease, neurofibromatosis type I, sarcoidosis, and various infections . To effectively study these associations:

• Genetic Analysis Approaches:

  • Case-control association studies with careful population stratification control

  • Family-based association studies for rare variants

  • Next-generation sequencing of the entire IL12RB1 locus including regulatory regions

  • Haplotype analysis to identify combinations of variants with functional significance

• Functional Validation Methods:

  • CRISPR-based introduction of variants into relevant cell lines

  • Patient-derived primary cell functional assays (cytokine responsiveness, pathogen control)

  • Reporter assays comparing wild-type and variant promoter/enhancer activity

  • Minigene splicing assays for variants in splice-relevant regions

• Molecular Phenotyping:

  • Quantitative RT-PCR to assess expression levels and splicing patterns

  • Flow cytometry to measure surface receptor levels

  • Phospho-flow to assess downstream signaling efficiency

  • RNA-seq for global transcriptional impact

• Clinical Correlation Strategies:

  • Thorough clinical phenotyping of variant carriers

  • Longitudinal follow-up to assess disease progression

  • Response to IL-12/IL-23 pathway-targeting therapies

  • Infection challenge models (where ethically appropriate)

• Integrative Approaches:

  • Combined genomic, transcriptomic, and epigenomic profiling

  • Systems biology modeling of IL-12/IL-23 pathway alterations

  • Machine learning to identify subtle genotype-phenotype correlations

This comprehensive approach allows researchers to move beyond statistical associations to establish causal relationships between IL12RB1 variants and disease mechanisms, potentially informing personalized therapeutic strategies.

How can researchers develop experimental models to test therapeutic targeting of IL12RB1 in inflammatory diseases?

Given IL12RB1's role in inflammatory diseases and its targeting in psoriasis treatments , developing robust experimental models is crucial:

• In Vitro Models:

  • Primary human cell systems with IL12RB1 expression modulation

  • Co-culture systems recapitulating tissue inflammation (e.g., skin, gut, joint)

  • Patient-derived organoids incorporating immune components

  • High-throughput screening platforms for drug discovery

• Animal Model Development:

  • Humanized mice expressing human IL12RB1

  • Tissue-specific or inducible expression/deletion models

  • Models incorporating human disease-associated polymorphisms

  • Reporter systems for in vivo monitoring of pathway activation

• Therapeutic Approach Evaluation:

  • Domain-specific antibodies targeting IL12RB1-cytokine interfaces

  • Small molecule inhibitors of downstream signaling components

  • Antisense oligonucleotides for isoform-specific modulation

  • Gene editing approaches for permanent correction

• Readout Systems:

  • Multi-parameter flow cytometry for immune cell phenotyping

  • Tissue-specific inflammation metrics

  • Systems-level transcriptomic/proteomic analysis

  • Functional recovery assessments

• Translational Considerations:

  • Ex vivo testing in patient samples

  • Biomarker development for patient stratification

  • Comparative efficacy versus established IL-12/IL-23 targeting approaches

  • Safety profiling with attention to infection susceptibility

When developing these models, researchers should consider the dual role of IL12RB1 in both pathogen resistance and autoimmunity , carefully designing studies to evaluate therapeutic windows that suppress pathological inflammation while preserving antimicrobial immunity.

What are the most rigorous approaches for studying IL12RB1 expression and function in patient-derived samples?

Working with patient-derived samples requires especially rigorous methodology:

• Sample Collection and Processing:

  • Standardized protocols for isolation of PBMCs, tissue biopsies

  • Immediate preservation options for RNA integrity (RNAlater, flash freezing)

  • Detailed documentation of patient characteristics and treatment status

  • Time-controlled processing to minimize ex vivo artifacts

• Expression Analysis:

  • Quantitative RT-PCR with isoform-specific primers

  • Flow cytometry with validated antibodies against different IL12RB1 domains

  • In situ hybridization for tissue localization

  • Single-cell approaches to capture cellular heterogeneity

• Functional Assessments:

  • Cytokine responsiveness assays (pSTAT4/pSTAT3 induction)

  • Pathogen growth restriction assays (M. tuberculosis, Salmonella)

  • T cell polarization and cytokine production

  • Receptor complex formation efficiency

• Genetic and Epigenetic Analysis:

  • Targeted sequencing of IL12RB1 locus

  • Methylation analysis of regulatory regions

  • Chromatin accessibility assessment

  • Long-read sequencing for complex structural variants

• Quality Control Measures:

  • Inclusion of appropriate healthy controls matched for age/sex/ethnicity

  • Technical replicates to assess measurement variability

  • Verification with multiple methodological approaches

  • Blinded analysis to prevent observer bias

• Longitudinal Considerations:

  • Consistency in sampling timing relative to disease activity

  • Before/after therapeutic intervention comparisons

  • Correlation with clinical outcomes and biomarkers

By adhering to these rigorous approaches, researchers can generate reliable data from patient-derived samples that accurately reflect the in vivo biology of IL12RB1 in different disease contexts.

What are the optimal storage and handling conditions for maintaining recombinant IL12RB1 stability and activity?

Proper storage and handling of recombinant IL12RB1 is critical for experimental reproducibility:

• Storage Recommendations:

  • Long-term storage: -20°C to -70°C for up to 12 months from receipt date

  • Medium-term storage: 2-8°C under sterile conditions after reconstitution for up to 1 month

  • Working stocks: Aliquot to minimize freeze-thaw cycles

• Reconstitution Protocol:

  • Lyophilized protein should be reconstituted at approximately 200 μg/mL in sterile PBS

  • Allow complete dissolution before using (gentle swirling rather than vortexing)

  • Filter sterilization may be necessary for certain applications

• Stability Considerations:

  • Avoid repeated freeze-thaw cycles which significantly reduce activity

  • Use a manual defrost freezer rather than auto-defrost

  • Monitor protein aggregation after reconstitution

• Quality Control Checks:

  • Regular activity testing using binding assays

  • Visual inspection for precipitation or color changes

  • SDS-PAGE analysis to confirm integrity after extended storage

• Application-Specific Handling:

  • For cell culture: Ensure sterility and test for endotoxin contamination

  • For structural studies: Verify monodispersity before experiments

  • For binding assays: Perform calibration curves with each new lot

Proper documentation of storage conditions, reconstitution date, and number of freeze-thaw cycles should be maintained for each lot to ensure experimental reproducibility and facilitate troubleshooting if activity issues arise.

What are the most effective validation methods to confirm the specificity and activity of recombinant IL12RB1 in experimental systems?

Thorough validation is essential before using recombinant IL12RB1 in experiments:

• Binding Specificity Validation:

  • Surface plasmon resonance with IL-12 and IL-23 as analytes

  • Competitive binding assays with known ligands

  • Cross-reactivity testing with related cytokines

  • Functional ELISA showing dose-dependent binding (ED50 of 3.00-30.0 ng/mL for high-quality protein)

• Structural Validation:

  • SDS-PAGE under reducing and non-reducing conditions showing expected molecular weight bands (62-79 kDa for His-tagged; ~110 kDa for Fc-fusion)

  • Western blotting with domain-specific antibodies

  • Mass spectrometry to confirm sequence and post-translational modifications

  • Circular dichroism to assess secondary structure integrity

• Functional Validation:

  • Cell-based reporter assays measuring STAT phosphorylation

  • Co-immunoprecipitation with IL12RB2 or IL23R

  • T cell proliferation or NK cell activation assays

  • Receptor complex formation analysis by FRET or BiFC

• Quality Control Metrics:

  • Purity assessment (>95% by silver-stained SDS-PAGE)

  • Endotoxin testing (<0.10 EU per 1 μg by LAL method)

  • Aggregation assessment by size exclusion chromatography

  • Glycosylation profiling for mammalian-expressed protein

• Negative Controls:

  • Heat-denatured protein

  • Competing/blocking antibodies

  • Structurally related but non-functional proteins

  • IL12RB1-deficient cell lines

Validation should be performed for each new lot of recombinant protein and should include positive and negative controls appropriate to the specific experimental system being used.

What are the key methodological considerations when designing experiments to study IL12RB1 isoform expression?

When investigating IL12RB1 isoform expression, researchers should consider several methodological factors:

• Primer/Probe Design for Detection:

  • Design primers spanning exon-exon junctions specific to each isoform

  • Include universal primers targeting conserved regions for normalization

  • Consider droplet digital PCR for absolute quantification of low-abundance isoforms

  • Design isoform-specific hydrolysis probes for maximum specificity

• Sample Preparation Considerations:

  • Extract RNA using methods that preserve integrity of full-length transcripts

  • Consider polyA selection versus rRNA depletion based on experimental goals

  • Include DNase treatment to prevent genomic DNA amplification

  • Use reverse transcriptase optimized for long or structured templates

• Cell Type and Stimulation Conditions:

  • Examine multiple immune cell subsets (T cells, NK cells, B cells, monocytes)

  • Include activation conditions known to induce IL12RB1 expression

  • Consider time-course experiments to capture dynamic regulation

  • Include inflammatory stimuli relevant to mycobacterial infection contexts

• Validation Approaches:

  • Confirm specificity of amplicons by sequencing

  • Use multiple detection methods (qPCR, Northern blot, RNA-Seq)

  • Include positive controls expressing known isoforms

  • Consider absolute quantification methods for accurate isoform ratios

• Advanced Technologies:

  • Long-read sequencing (PacBio, Oxford Nanopore) for unambiguous isoform detection

  • Single-cell RNA-Seq to assess cell-to-cell heterogeneity

  • Targeted RNA-Seq with custom capture for deep coverage of the IL12RB1 locus

  • Nascent RNA capture to assess transcriptional regulation